Kevin Gooch, MD
Internal Medicine · Whitesburg, KYNPI 1164415576
Payments from drug & device makers
Across 169 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$610
- GSK$351
- AbbVie$331
- Pfizer$176
- Lilly USA, LLC$150
- Lundbeck LLC$137
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,94299%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $610 |
| GSK | 24 | $351 |
| AbbVie(2 entities) | 16 | $331 |
| Pfizer | 10 | $176 |
| Lilly USA, LLC | 9 | $150 |
| Lundbeck LLC | 6 | $137 |
| Abbott | 8 | $130 |
| AstraZeneca | 8 | $126 |
| Amgen | 7 | $109 |
| Axsome Therapeutics, Inc. | 4 | $78 |
| Boehringer Ingelheim | 4 | $70 |
| Bayer | 4 | $67 |
| Phathom Pharmaceuticals, Inc. | 5 | $65 |
| E.r. Squibb & Sons, L.L.C. | 4 | $60 |
| Esperion Therapeutics, Inc. | 3 | $56 |
| Sumitomo Pharma America, Inc. | 3 | $52 |
| Medtronic | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 1 | $40 |
| Astellas Pharma US Inc | 1 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Tonix Medicines, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Evoke Pharma, Inc. | 1 | $17 |
| Teleflex LLC | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Mylan Specialty L.p. | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Novartis | 1 | $12 |
How this compares
$2,962 in reported general payments places this provider in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 189 | $182,023 |
| OzempicSemaglutide | 139 | $167,364 |
| JardianceEmpagliflozin | 185 | $142,950 |
| FarxigaDapagliflozin Propanediol | 158 | $133,176 |
| TrulicityDulaglutide | 96 | $116,601 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $91,931 |
| MounjaroTirzepatide | 72 | $84,666 |
| JanuviaSitagliptin Phosphate | 34 | $38,890 |
| XareltoRivaroxaban | 18 | $27,417 |
| MyrbetriqMirabegron | 25 | $23,758 |
| SymbicortBudesonide/Formoterol Fumarate | 77 | $22,375 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $21,261 |
| Spiriva RespimatTiotropium Bromide | 38 | $19,982 |
| GlyxambiEmpagliflozin/Linagliptin | 18 | $15,923 |
| TradjentaLinagliptin | 24 | $14,225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $150 | $201,267168 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Glyxambi, Tradjenta | $70 | $193,080265 claims |
| PfizerEliquis | $176 | $182,023189 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $126 | $176,811267 claims |
| Novo NordiskOzempic | $610 | $167,364139 claims |
| GSKTrelegy Ellipta | $351 | $91,931116 claims |
| Astellas Pharma US IncMyrbetriq | $34 | $23,75825 claims |
| AbbVieLinzess, Synthroid | $331 | $11,57067 claims |
| Esperion Therapeutics, Inc.Nexletol | $56 | $9,10312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Whitesburg
- Fares KhaterWhitesburg$412K
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.